amiloride + thiazolidinedione

Amiloride + thiazolidinedione represents a theoretical or investigational drug combination not currently marketed as a fixed-dose or branded product. Amiloride is a potassium-sparing diuretic that inhibits epithelial sodium channels, thereby preventing sodium reabsorption and potassium loss in the distal nephron. Thiazolidinediones are a class of insulin-sensitizing drugs (such as pioglitazone or rosiglitazone) used primarily in type 2 diabetes mellitus. Amiloride has been reported to mitigate edema induced by thiazolidinedione use, as fluid retention is a known side effect of thiazolidinediones due to their effect on renal sodium handling. The combination would aim to combine the glycemic benefits of thiazolidinediones with the potassium-conserving diuretic effect of amiloride to reduce or treat thiazolidinedione-induced edema[2]. Direct clinical data or approved pharmaceutical products for this specific combination are not available, and the reference context is primarily off-label use or investigational combinations.